SYRS - Why Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today? | Benzinga
Syros Pharmaceuticals Inc (NASDAQ: SYRS) released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
In December 2022, Syros reported data from the safety lead-in portion of SELECT-AML-1, in which five of six response evaluable patients (83%) achieved CR/CRi.
As of November 13, 2023, 23 newly diagnosed unfit AML patients positive for RARA overexpression had enrolled.
The primary endpoint (CR/CRi rate) was 100% among response evaluable patients (nine of nine) treated with tamibarotene, venetoclax, and azacitidine, as ...